Thomas J. Weber
About
In The Last Decade
Thomas J. Weber
60 papers receiving 3.5k citations
Hit Papers
Peers
Comparison fields: 5 of 132
- Endocrinology, Diabetes and Metabolism 1.7k
- Molecular Biology 1.1k
- Nephrology 869
- Genetics 703
- Pharmacology 513
Countries citing papers authored by Thomas J. Weber
This map shows the geographic impact of Thomas J. Weber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas J. Weber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas J. Weber more than expected).
Fields of papers citing papers by Thomas J. Weber
This network shows the impact of papers produced by Thomas J. Weber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas J. Weber. The network helps show where Thomas J. Weber may publish in the future.
Co-authorship network of co-authors of Thomas J. Weber
This figure shows the co-authorship network connecting the top 25 collaborators of Thomas J. Weber. A scholar is included among the top collaborators of Thomas J. Weber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas J. Weber. Thomas J. Weber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 0 | |
| 4 | 36 | |
| 5 | 5 | |
| 6 | Pharmacokinetics and pharmacodynamics of a human monoclonal anti‐FGF23 antibody (KRN23) in the first multiple ascending‐dose trial treating adults with X‐linked hypophosphatemia | 1 |
| 7 | 44 | |
| 8 | 114 | |
| 9 | Assessment of Quality of Life Data After 4 Monthly S.C. Doses of a Human Monoclonal Anti-Fibroblast Growth Factor 23 Antibody (KRN23) in Adults with X-linked Hypophosphatemia | 1 |
| 10 | Hypophosphatasia: Enzyme Replacement Therapy (Asfotase Alfa) Decreases TNSALP Substrate Accumulation And Improves Functional Outcomes In Affected Adolescents And Adults. | 6 |
| 11 | 27 | |
| 12 | 19 | |
| 13 | 15 | |
| 14 | Management der oralen Antikoagulation bei Operationen und anderen invasiven Eingriffen | 1 |
| 15 | Fixkombination Enalapril/Nitrendipin* in der täglichen Praxis - Effektivität und Verträglichkeit bei 1.262 österreichischen Hypertonikern | 1 |
| 16 | 15 | |
| 17 | How bone density testing influenced osteoporosis treatment in a community hospital. | 0 |
| 18 | 5 | |
| 19 | 22 | |
| 20 | 6 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.